Key Development in Laxative Industry

FDA Approval of Lactitol for Chronic Idiopathic Constipation

Lactitol was approved by the FDA in 2020 for adults with chronic idiopathic constipation, a notable advancement in dealing with this issue. Lactitol is an artificial disaccharide used as an osmotic laxative that pulls water into the colon, allowing stools to move through. Lactitol comes as a powder to be mixed with water or juice for easier ingestion. This clearance provides another treatment choice for individuals who experience chronic constipation, a quick and easy alternative to standard approaches. It extends the range of potential therapy, which enhances patient outcomes and satisfaction.

Purdue Pharma’s Expansion in Digestive Health Products

Purdue Pharma L.P. extended its portfolio of gastrointestinal health products in 2021 with the introduction of two new Senokot Dietary Supplement Products. The Senokot Laxative Gummies, in a blueberry pomegranate flavor, utilize the natural laxative properties of senna extract to gently ease constipation during the night. Senokot Laxative Tea, the company's new natural and soothing way to ease constipation and flavored with floral and cinnamon undertones, has been released. Purdue Pharma's portfolio is now more diversified due to these new products, which meet consumers who seek flavorful and gentle digestive health remedies while maintaining the efficacy of traditional senna-based treatments.

JB Pharma introduced Ranraft, a new treatment for gastroesophageal reflux disease (GERD), in 2022, strengthening its foothold in the gastrointestinal segment. This groundbreaking treatment aims to offer efficient relief to GERD sufferers by tackling the root causes of the condition. The introduction of Ranraft strengthens JB Pharma's product line and reflects the company's commitment to offering innovative digestive health treatments. By serving the interests of GERD patients, JB Pharma establishes itself as a leading firm in the digestive health sector dedicated to offering quality therapies for prevalent gastrointestinal issues.

In 2019, the Laxatives industry was worth nearly US$ 396.3 million and is anticipated to hold a compound annual growth rate (CAGR) of 5.0% during the forecast period of 2019 to 2027.

Key Drivers and Market Segmentation

The increasing prevalence of constipation, one of the most frequently diagnosed gastrointestinal conditions worldwide, is the major driver for this growth. In order to cater to the diverse needs of patients, the market has a variety of product categories like bulk-forming agents, emollient agents, stimulant agents, and others. The growth of the market is also supported by the presence of prescription and over-the-counter drugs as well as the variety of administration routes like oral and rectal.